Video Programs

Explore advanced treatment options for gastrointestinal neuroendocrine tumors, focusing on real-world case studies and emerging clinical data.

Leyla O. Shune, MD, looks to the future of treatment for patients with chronic graft-versus-host disease (cGVHD).

Explore innovative combination strategies for chronic GVHD treatment, focusing on emerging therapies and their potential to enhance patient outcomes.

Leyla O. Shune, MD, discusses sequencing agents in the in current treatment paradigm for chronic graft-versus-host disease, given the multitude of available FDA-approved agents and additional treatments emerging on the horizon.

Explore the complexities of interpreting clinical trial results versus real-world experiences in chronic GVHD treatment options.

Explore effective third-line treatments for chronic GVHD, focusing on the latest FDA-approved therapies and their impact on patient outcomes.

This segment examines optimal care for patients with early-stage non–small cell lung cancer (NSCLC) relying on coordinated multidisciplinary collaboration.

This case examines effective management of early-stage non–small cell lung cancer (NSCLC) requiring integrating imaging, laboratory results, and molecular profiling to guide therapy.

Leyla O. Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease.

A patient with chronic graft-versus-host disease faces treatment challenges, highlighting the need for effective management strategies post-transplant.

A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance of multidisciplinary evaluation.

New findings reveal promising advancements in treating relapsed mantle cell lymphoma with BCL-2 inhibitors and novel agents, enhancing patient outcomes.

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved testing strategies and healthcare access.

Ramez N. Eskander, MD, discusses the optimal use of lenvatinib/pembrolizumab in clinical practice for patients with endometrial cancer. He provides advice for integrating this regimen into the treatment paradigm.

Real-world data reinforces the efficacy and tolerability of lenvatinib and pembrolizumab for treating recurring endometrial cancer.

In this final segment, Dr Luskin discusses treatment sequencing considerations in blastic plasmacytoid dendritic cell neoplasm (BPDCN), with a focus on integrating targeted therapy and allogeneic stem cell transplantation.

Recent studies highlight the effectiveness of lenvatinib and pembrolizumab in improving overall survival for patients with prior therapy in endometrial cancer.

This segment addresses the clinical implications of disease burden in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a condition that frequently presents with extensive skin involvement or other high-burden manifestations.

Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting.

Endometrial cancer treatment evolves with molecular insights, enhancing patient outcomes through tailored therapies and innovative clinical trials.

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective time-limited therapy options.

This segment focuses on safety considerations associated with tagraxofusp in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), with an emphasis on early toxicity recognition in community oncology settings

In this segment, Dr Luskin examines how patient-related factors influence treatment decisions in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a disease that predominantly affects older adults

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are steroid refractory/dependent. She also discusses treatment approaches and results with these agents in clinical trials and in real-world settings.

Remaining Obstacles to Widespread Use of MRD Detection in TNBC

Design and Function of Oncodetect Assay for MRD Detection